Axsome Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AXSM and other ETFs, options, and stocks.

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. 

CEO
Herriott Tabuteau
CEOHerriott Tabuteau
Employees
683
Employees683
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2012
Founded2012
Employees
683
Employees683

AXSM Key Statistics

Market cap
6.84B
Market cap6.84B
Price-Earnings ratio
-29.03
Price-Earnings ratio-29.03
Dividend yield
Dividend yield
Average volume
565.74K
Average volume565.74K
High today
$135.80
High today$135.80
Low today
$131.68
Low today$131.68
Open price
$134.66
Open price$134.66
Volume
577.46K
Volume577.46K
52 Week high
$139.13
52 Week high$139.13
52 Week low
$75.56
52 Week low$75.56

Stock Snapshot

With a market cap of 6.84B, Axsome Therapeutics(AXSM) trades at $135.69. The stock has a price-to-earnings ratio of -29.03.

During the trading session on 2025-11-06, Axsome Therapeutics(AXSM) shares reached a daily high of $135.80 and a low of $131.68. At a current price of $135.69, the stock is +3.0% higher than the low and still -0.1% under the high.

Trading activity shows a volume of 577.46K, compared to an average daily volume of 565.74K.

Over the past 52 weeks, Axsome Therapeutics(AXSM) stock has traded between a high of $139.13 and a low of $75.56.

Over the past 52 weeks, Axsome Therapeutics(AXSM) stock has traded between a high of $139.13 and a low of $75.56.

AXSM News

Simply Wall St 3h
Should Axsome Therapeutics' Revenue Surge and Shelf Filing Spark a New Investor Outlook?

Axsome Therapeutics reported third-quarter 2025 earnings, posting revenues of US$170.99 million, up from US$104.76 million in the prior year, as well as a reduc...

Should Axsome Therapeutics' Revenue Surge and Shelf Filing Spark a New Investor Outlook?
TipRanks 1d
Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges

Axsome Therapeutics Inc. ((AXSM)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage...

TipRanks 2d
Axsome Therapeutics Reports Strong Q3 2025 Growth

Axsome Therapeutics Inc. ( (AXSM) ) has released its Q3 earnings. Here is a breakdown of the information Axsome Therapeutics Inc. presented to its investors. E...

Analyst ratings

100%

of 20 ratings
Buy
100%
Hold
0%
Sell
0%

More AXSM News

TipRanks 3d
Axsome Therapeutics Reports 63% Revenue Growth in Q3 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

People also own

Based on the portfolios of people who own AXSM. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.